ArticleBrain communications2025
Association between amyloid-β42 levels and neuropsychiatric symptoms in Alzheimer's disease trials.
Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Reductions in neuropsychiatric symptoms after lecanemab treatment and their associations with imaging markers of β-amyloid clearance.The journal of prevention of Alzheimer's disease · 2026Article
- Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer's Disease.Molecules (Basel, Switzerland) · 2025Review
- Physics of Protein Aggregation in Normal and Accelerated Brain Aging.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025Review
- Neuropsychiatric Symptoms and White Matter Hyperintensities in Older Cognitively Unimpaired Men Versus Women.International journal of geriatric psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research on how Alzheimer's disease drugs impact neuropsychiatric symptoms is limited. Given the link between changes in cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels and cognitive and clinical outcomes after anti-Aβ treatments, we hypothesized a similar association exists with neuropsychiatric symptoms. We conducted a meta-analysis of anti-Aβ drugs clinical trials to evaluate whether the changes in cerebrospinal Aβ42 levels are associated with neuropsychiatric symptoms, as measured by the Neuropsychiatric Inventory and if any such effect is mediated by changes in cognitive performance, as measured by the Mini-Mental State Examination. Data from 10 trials involving 10 746 Alzheimer's disease patients were included. Decreases in Aβ42 levels were associated with worsening Neuropsychiatric Inventory scores (regression coefficient: -0.68; 95% confidence interval: -1.07 to -0.29;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.